The contents of the presentations above are designed for educational and scientific exchange purposes and are not promotional. They may contain information on investigational products or investigational uses of approved products. No conclusions regarding safety and/or efficacy for such investigational products or uses may be made.
This study evaluated sonrotoclax (an investigational BCL2 inhibitor) in patients with relapsed/refractory mantle cell lymphoma (R/R MCL) who had previously received anti-CD20-based therapy and at least one BTK inhibitor. Among 125 patients, sonrotoclax was well tolerated and demonstrated clinical activity, with a 53% response rate and a median response duration of nearly 16 months. Treatment-emergent adverse events (TEAEs) of any grade occurring in ≥20% of patients were blood-related, well tolerated, and manageable. TEAEs led to treatment discontinuation in 16 patients (13.9%) and death in 15 patients (13.0%). 42 deaths occurred but most were due to disease progression (n=29). These results support further investigation of sonrotoclax as a potential treatment option for patients with R/R MCL.
